Oracle Life Sciences has been named a ‘Leader’ in the Everest Group Electronic Data Capture (EDC) Products PEAK Matrix Assessment 2024. Oracle was recognized for its comprehensive EDC capabilities and ease of integration. Oracle’s EDC capabilities enable pharmaceutical companies and CROs to collect data from any source, harmonize it in a single place, and apply analytics to draw out valuable clinical insights from the data across multiple studies.

“Being named a leader in EDC by Everest Group underscores our decades-long commitment to delivering the technology our customers need to securely manage the vast amounts of data required to run clinical trials,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our connected, AI-driven solutions we are continuing to provide the innovations that will further enhance the data collection and analysis from clinical trials and clinical care to help accelerate trials and get critical treatments to market faster.

Our vision goes beyond traditional EDC to create an interoperable, intelligent data ecosystem that unifies disparate data, unlocks AI-driven insights, accelerates innovative drug development, and shapes the future of healthcare.”

The Everest Group PEAK Matrix is a composite index of a range of distinct metrics related to a provider’s capability and market impact. Everest Group assessed the capabilities of 20 EDC providers, encompassing collection, review, and processing of clinical trial data.

Oracle Life Sciences was noted as a leader for:

• A robust integration network featuring a variety of data sources and flexible implementations, as showcased by a willingness to customize offerings per clients’ needs.
• Good brand recall and familiarity with sites and sponsors due to a strong history in the EDC landscape.
• High client product satisfaction ratings for security, governance, and compliance.
• Flexibility in customizations and willingness to model offerings for clients' unique needs.

“The EDC market has evolved significantly due to the increasing complexity of clinical trials, diverse real-world data sources, and the demand for efficient data management solutions, leading providers to develop comprehensive platforms that integrate data capture with advanced analytics and AI. There is also a clear trend towards enhancing user experience through low-code functionalities that allow workflow customization without extensive technical knowledge, addressing the need for real-time data insights and improved data accuracy,” said Nisarg Shah, Practice Director at Everest Group. “Oracle's Inform EDC integrates with patient data sources, including EHR databases, claims, and RCM data, providing seamless data management capabilities across clinical trials. Clients appreciate the flexibility of the EDC platform, which allows for effortless eCRF creation, data validation checks, and protocol customizations tailored to their needs. Oracle's heritage in the EDC market, combined with its strong background in security and compliance, has positioned Oracle as a Leader in the Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix Assessment 2024.”

The Everest Group PEAK Matrix is a proprietary framework for assessing the relative market success and overall capability of service providers based on performance, experiences, ability, and knowledge. Each service provider is comparatively assessed on two dimensions: market success and delivery capabilities. Market success is measured by revenue, number of clients, and year-over-year growth. Delivery capability is measured by scale of operations, scope, technology and innovation, delivery footprint, and buyer satisfaction. The resulting matrix categorizes service providers as Leaders, Major Contenders, and Aspirants.

To read the full Everest Group PEAK Matrix report, visit https://www2.everestgrp.com/reportaction/EGR-2024-72-R-6637/Marketing.